Bizengri (Zenocutuzumab-Zbco) | aBLA Filing Intelligence & Biosimilar Opportunity

Bizengri

Bizengri is an IV antibody therapy for adults with advanced non-small cell lung cancer or pancreatic cancer driven by NRG1 gene fusions, used after standard treatments fail. It blocks the fusion protein’s signaling to help shrink tumors and control disease progression

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Zenocutuzumab-Zbco
Innovator :

MERUS N.V.
Approval Date :

04-Dec-24
Data Exclusivity Expiry :

04-Dec-28
Market Exclusivity Expiry :

04-Dec-36
Dosage Form :

Injection
Strength :

375MG/18.75ML
Therapeutic Category :

Immunomodulators
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2026 :

1
2027 :

6
2028 :

10
2029 :

13
2030 :

17
2031 :

21
2032 :

25

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Bizengri

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?